HCWB ▼ -2.0% - HCW Biologics Inc.
$HCWB - HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics shares fell 2.0% today despite announcing an exclusive distribution agreement with Akron Biotech to commercialize HCW11-006, a reagent designed to enhance human CAR-T cell production. The decline suggests investors may have been disappointed by the scope of the deal or anticipated a broader commercialization announcement.
08-SEP-2026 08:50 AM ET
Share this post
More filings for $HCWB
View full $HCWB filing history →💬 Comments
Loading comments…
Leave a comment
